

Bacillus anthracis spore antigen (SA27): sc-51877

BACKGROUND

The genus *Bacillus* consists of aerobic, Gram-positive, spore-forming, rod-shaped bacterium. *Bacillus anthracis* causes anthrax, an acute infectious disease of cattle, sheep, goats, camels, antelopes and other herbivores that is highly lethal in some forms. Infection can occur in humans when exposed to infected animals or tissue from infected animals via three routes: cutaneous, inhalation and intestinal. *B. anthracis* spores persist (as spores) in the soil for many years as they are resistant to heat, cold, radiation, desiccation and disinfectants. *In vivo*, *B. anthracis* produces a polypeptide (polyglutamic acid) capsule that protects it from phagocytosis. The virulence factors of *B. anthracis* are its capsule and three component toxin, both encoded on plasmids.

REFERENCES

1. Dragon, D.C. and Rennie, R.P. 1995. The ecology of anthrax spores: tough but not invincible. *Can. Vet. J.* 36: 295-301.
2. Varughese, M., Chi, A., Teixeira, A.V., Nicholls, P.J., Keith, J.M. and Leppla, S.H. 1998. Internalization of a *Bacillus anthracis* protective antigen-c-Myc fusion protein mediated by cell surface anti-c-Myc antibodies. *Mol. Med.* 4: 87-95.
3. Turnbull, P.C. 1999. Definitive identification of *Bacillus anthracis*—a review. *J. Appl. Microbiol.* 87: 237-240.
4. Cohen, S., Mendelson, I., Altboum, Z., Kobiler, D., Elhanany, E., Bino, T., Leitner, M., Inbar, I., Rosenberg, H., Gozes, Y., Barak, R., Fisher, M., Kronman, C., Velan, B. and Shafferman, A. 2000. Attenuated nontoxinogenic and nonencapsulated recombinant *Bacillus anthracis* spore vaccines protect against anthrax. *Infect. Immun.* 68: 4549-4558.
5. Mock, M. and Fouet, A. 2001. Anthrax. *Ann. Rev. Microbiol.* 55: 647-671.
6. Williams, D.D., Turnbough, C.L., Jr. 2004. Surface layer protein EA1 is not a component of *Bacillus anthracis* spores but is a persistent contaminant in spore preparations. *J. Bacteriol.* 186: 566-569.
7. Crawford, M.A., Aylott, C.V., Bourdeau, R.W. and Bokoch, G.M. 2006. *Bacillus anthracis* toxins inhibit human neutrophil NADPH oxidase activity. *J. Immunol.* 176: 7557-7565.
8. Yan, M., Roehrl, M.H., Basar, E. and Wang, J.Y. 2008. Selection and evaluation of the immunogenicity of protective antigen mutants as anthrax vaccine candidates. *Vaccine* 26: 947-955.
9. Jinbiao, L., Dong, W., Guozhi, W. and Yefu, W. 2009. High-level expression and single-step purification of recombinant *Bacillus anthracis* protective antigen from *Escherichia coli*. *Biotechnol. Appl. Biochem.* 52: 107-112.

SOURCE

Bacillus anthracis spore antigen (SA27) is a mouse monoclonal antibody raised against *Bacillus anthracis* spore extract.

PRODUCT

Each vial contains 100 µg IgG_{2a} in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

APPLICATIONS

Bacillus anthracis spore antigen (SA27) is recommended for detection of Bacillus anthracis spore antigen by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000).

Molecular Weight of Bacillus anthracis spore antigen: 92 kDa.

STORAGE

Store at 4° C, ****DO NOT FREEZE****. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.